Evidence map›Paper›PMID 36495416›Full record

ArticleMolecular biotechnology2023

Construction of Lentiviral Vector for miR-217 Overexpression and Knockdown and Its Effect on CML.

Xin Yang, Huihui Jiang, Chengming Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xin Yang *The Clinical Laboratory, Yantai Yuhuangding Hospital, 20 Yuhuangding East Road, Yantai, 264000, Shandong, China.
Huihui Jiang *Clinical Laboratory, Qingdao Central Hospital, The Second Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Chengming SunThe Clinical Laboratory, Yantai Yuhuangding Hospital, 20 Yuhuangding East Road, Yantai, 264000, Shandong, China. chengmingsun@163.com.ORCID http://orcid.org/0000-0002-8065-9053
Yuhuangding Hospital · CNQingdao University · CN

Funding

major scientific and technological innovation projects of the Shandong Province of China 2019JZZY011018Science and Technology Plan Project of Wenzhou, China 2019YD004Yantai Science and Technology Plan Project of China 2019MSGY133
6 · The paper itself

Abstract

We attempted to construct a myeloid leukemia cell strain for stable overexpression and knock-down of miR-217 and explored the possible mechanism underlying miR-217 in chronic myeloid leukemia (CML). MiR-217 overexpression and the knock-down lentiviral vector with puromycin resistance were constructed and packaged within recombinant lentivirus. Stably transfected K562 cells were obtained through puromycin screening, and the qPCR assay detected the relative expression of the target gene. The proliferation, apoptosis, and methylation level of PER2 within cultured cells were detected using the CCK-8 assay, flow cytometry, and TaqMan real‑time fluorescence quantitative methylation-specific PCR. qPCR and Western blot detected the expression of miR-217-related genes within the constructed K562 cell model. Colony PCR and sequencing proved that recombinant lentivirus expression vectors pSE16 and pSE17 were correctly constructed. The lentivirus titer was 2.95 × 10

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMicroRNAsApoptosisCell Line, TumorCell ProliferationCells, CulturedHumansK562 CellsLentivirusMicroRNAsMIRN217 microRNA, humanCMLDNMT3ALentiviralMiR-217PER2

Identifiers

PMID36495416
OpenAlexW4311025545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.